Alkem Laboratories ALKE.NS ALKEM IN EQUITY: HEALTH CARE & PHARMACEUTICALS 1QFY27: Miss driven by costs, not demand Maintain Buy on domestic core and CDMO/MedTech optionality 1QFY27: Misses Street estimates on slower domestic growth and elevated costs Alkem's 1QFY27 results missed Street estimates ( Fig. 2 ) , with domestic formulation sales growth trailing most industry peers and operating costs escalating at a faster clip as the company scaled investments in new business verticals. Revenue/EBITDA/PAT came ...